ANL Stock - Adlai Nortye Ltd.
Unlock GoAI Insights for ANL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $5.00M | N/A | $45.73M | N/A |
| Gross Profit | $-1,870,937 | $5.00M | $-2,038,574 | $45.73M | $-1,508,497 |
| Gross Margin | N/A | 100.1% | N/A | 100.0% | N/A |
| Operating Income | $-54,895,520 | $-67,551,000 | $-67,270,000 | $-8,646,000 | $-26,100,390 |
| Net Income | $-51,895,016 | $-104,871,000 | $-58,790,000 | $-56,678,000 | $-63,378,317 |
| Net Margin | N/A | -2099.2% | N/A | -124.0% | N/A |
| EPS | $-4.89 | $-15.42 | $-6.93 | $-6.66 | $-7.62 |
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 2nd 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| September 4th 2024 | H.C. Wainwright | Initiation | Buy | $9 |
| October 24th 2023 | Cantor Fitzgerald | Initiation | Overweight | $30 |
Earnings History & Surprises
ANLEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 7, 2025 | $-0.18 | $-0.18 | 0.0% | = MET |
Q2 2025 | Apr 30, 2025 | $-0.53 | $-0.22 | +58.5% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.53 | $-0.22 | +58.5% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.06 | $-0.53 | +50.1% | ✓ BEAT |
Q2 2024 | Apr 20, 2024 | $-0.38 | $-0.65 | -70.5% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | — | $-0.53 | — | — |
Q3 2023 | Sep 30, 2023 | $-0.24 | $-0.65 | -170.0% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | — | $-2.49 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.59 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.87 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.87 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.14 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.44 | — | — |
Q1 1970 | Jan 1, 1970 | $-0.38 | — | — | — |
Frequently Asked Questions about ANL
What is ANL's current stock price?
What is the analyst price target for ANL?
What sector is Adlai Nortye Ltd. in?
What is ANL's market cap?
Does ANL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ANL for comparison